Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Christodoulos Pipinikas"'
Autor:
Jeroen van Dorp, Christodoulos Pipinikas, Britt B. M. Suelmann, Niven Mehra, Nick van Dijk, Giovanni Marsico, Maurits L. van Montfoort, Sophie Hackinger, Linde M. Braaf, Tauanne Amarante, Charlaine van Steenis, Kirsten McLay, Antonios Daletzakis, Daan van den Broek, Maaike W. van de Kamp, Kees Hendricksen, Jeantine M. de Feijter, Thierry N. Boellaard, Richard P. Meijer, Toine G. van der Heijden, Nitzan Rosenfeld, Bas W. G. van Rhijn, Greg Jones, Michiel S. van der Heijden
Publikováno v:
Nature Medicine, 29, 3, pp. 588-592
Nature Medicine, 29, 588-592
Nature Medicine, 29, 588-592
Item does not contain fulltext Cohort 1 of the phase 1B NABUCCO trial showed high pathological complete response (pCR) rates with preoperative ipilimumab plus nivolumab in stage III urothelial cancer (UC). In cohort 2, the aim was dose adjustment to
Autor:
Susanne Flach, Karen Howarth, Sophie Hackinger, Christodoulos Pipinikas, Pete Ellis, Kirsten McLay, Giovanni Marsico, Tim Forshew, Christoph Walz, Christoph A. Reichel, Olivier Gires, Martin Canis, Philipp Baumeister
Publikováno v:
Br. J. Cancer 126, 1186–1195 (2022)
Background Head and neck squamous cell carcinoma (HNSCC) remain a substantial burden to global health. Cell-free circulating tumour DNA (ctDNA) is an emerging biomarker but has not been studied sufficiently in HNSCC. Methods We conducted a single-cen
Autor:
Susanne Flach, Karen Howarth, Sophie Hackinger, Christodoulos Pipinikas, Pete Ellis, Kirsten McLay, Giovanni Marsico, Christoph Walz, Christoph A. Reichel, Olivier Gires, Martin Canis, Philipp Baumeister
Publikováno v:
Abstract- und Posterband - 93. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn Interface - Fokus Mensch im Zeitalter der technisierten Medizin.
Autor:
Matt Lechner, Yoko Takahashi, Mario Turri-Zanoni, Jacklyn Liu, Nicholas Counsell, Mario Hermsen, Raman Preet Kaur, Tianna Zhao, Murugappan Ramanathan, Volker H. Schartinger, Oscar Emanuel, Sam Helman, Jordan Varghese, Jozsef Dudas, Herbert Riechelmann, Susanne Sprung, Johannes Haybaeck, David Howard, Nils Wolfgang Engel, Sarah Stewart, Laura Brooks, Jessica C. Pickles, Thomas S. Jacques, Tim R. Fenton, Luke Williams, Francis M. Vaz, Paul O'Flynn, Paul Stimpson, Simon Wang, S. Alam Hannan, Samit Unadkat, Jonathan Hughes, Raghav Dwivedi, Cillian T. Forde, Premjit Randhawa, Simon Gane, Jonathan Joseph, Peter J. Andrews, Gary Royle, Alessandro Franchi, Roberta Maragliano, Simonetta Battocchio, Helen Bewicke-Copley, Christodoulos Pipinikas, Amy Webster, Chrissie Thirlwell, Debbie Ho, Andrew Teschendorff, Tianyu Zhu, Christopher D. Steele, Nischalan Pillay, Bart Vanhaesebroeck, Ahmed Mohyeldin, Juan Fernandez-Miranda, Ki Wan Park, Quynh-Thu Le, Robert B. West, Rami Saade, R. Peter Manes, Sacit Bulent Omay, Eugenia M. Vining, Benjamin L. Judson, Wendell G. Yarbrough, Maddalena Sansovini, Nicolini Silvia, Ilaria Grassi, Alberto Bongiovanni, David Capper, Ulrich Schüller, Selvam Thavaraj, Ann Sandison, Pavol Surda, Claire Hopkins, Marco Ferrari, Davide Mattavelli, Vittorio Rampinelli, Fabio Facchetti, Piero Nicolai, Paolo Bossi, Oswaldo A. Henriquez, Kelly Magliocca, C. Arturo Solares, Sarah K. Wise, Jose L. Llorente, Zara M. Patel, Jayakar V. Nayak, Peter H. Hwang, Peter D. Lacy, Robbie Woods, James P. O'Neill, Amrita Jay, Dawn Carnell, Martin D. Forster, Masaru Ishii, Nyall R. London, Diana M. Bell, Gary L. Gallia, Paolo Castelnuovo, Stefano Severi, Valerie J. Lund, Ehab Y. Hanna
Publikováno v:
Eur J Cancer
Introduction: olfactory neuroblastoma (ONB) is a rare cancer of the sinonasal region. We provide a comprehensive analysis of this malignancy with molecular and clinical trial data on a subset of our cohort to report on the potential efficacy of somat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1ac81d3fcbeb85df6a377f39c36ac57
http://hdl.handle.net/11568/1132326
http://hdl.handle.net/11568/1132326
Autor:
Jeroen van Dorp, Christodoulos Pipinikas, Nick van Dijk, Greg Jones, Alberto Gil-Jimenez, Giovanni Marsico, Maurits L. van Montfoort, Sophie Hackinger, Linde Braaf, Kirsten McLay, Daan van den Broek, Bas W. Van Rhijn, Nitzan Rosenfeld, Michiel S. van der Heijden
Publikováno v:
Cancer Research. 82:1273-1273
Patients (pts) with stage III (cT3-4aN0M0 or cT1-4aN1-3M0) urothelial cancer (UC) have a poor prognosis. In NABUCCO cohort 1, 24 stage III UC pts were treated with ipilimumab (ipi) plus nivolumab (nivo) followed by radical surgery (day 1: ipi 3 mg/kg
Autor:
Miguel Garcia Pardo, Kasia Czarnecka, Jennifer H. Law, Alexandra Maria Salvarrey, Roxanne Fernandes, Jason Fan, Lucy Corke, Lisa W Le, Thomas K. Waddell, Kazuhiro Yasufuku, Geoffrey Liu, Frances A. Shepherd, Penelope Ann Bradbury, Adrian G. Sacher, Tracy Stockley, Prodipto Pal, Ming Sound Tsao, Karen Howarth, Christodoulos Pipinikas, Natasha B. Leighl
Publikováno v:
Journal of Clinical Oncology. 40:3039-3039
3039 Background: Molecular profiling of tumor tissue is the gold standard for treatment decision making in advanced non-small cell lung cancer. Results may be delayed or unavailable due to insufficient tissue samples or prolonged wait times for biops
Autor:
Wolfgang Janni, Jens Huober, Sophia Huesmann, Christodoulos Pipinikas, Tatjana Braun, Volkmar Müller, Giovanni Marsico, Angelina Fink, Paula Freire-Pritchett, Karin Koretz, Charlene Knape, Amelie deGregorio, Brigitte Rack, Thomas WP Friedl, Lisa Wiesmueller, Peter Möller, Karen Howarth, Klaus Pantel, Nitzan Rosenfeld
Publikováno v:
Cancer Research. 82:P2-01
BACKGROUNDDetection of minimal residual disease (MRD) using circulating tumor DNA (ctDNA) represents an attractive alternative to imaging, currently considered the gold standard in routine surveillance of early breast cancer (BrCa) following primary
Autor:
Christoph Walz, Giovanni Marsico, Karen Howarth, Susanne Flach, Philipp Baumeister, Martin Canis, Olivier Gires, Sophie Hackinger, Christodoulos Pipinikas, Kirsten McLay
Publikováno v:
Cancer Research. 81:553-553
Introduction Head and neck squamous cell carcinoma (HNSCC) remains a substantial burden to global health. Despite evolving therapies, 5-year survival is less than 50% and unlike other cancers, reliable biomarkers to monitor treatment response do not